We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 12, 2024 Granted FDA approval of LYMPHIR™ for the...
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. PR Newswire CRANFORD, N.J., Aug. 12, 2024 LYMPHIR™ for the treatment of cutaneous T-cell...
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments PR Newswire CRANFORD, N.J., Aug. 12, 2024 Management call scheduled for Tuesday, August 13, 2024, at 8:30...
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on...
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma PR...
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1865 | 13.0101151029 | 14335 | 16725 | 13930 | 340937 | 14648.5066584 | DE |
4 | 260 | 1.63111668758 | 15940 | 16725 | 13745 | 291267 | 15068.048435 | DE |
12 | -140 | -0.856793145655 | 16340 | 16725 | 12250 | 612992 | 14952.2624395 | DE |
26 | -225 | -1.3698630137 | 16425 | 17980 | 12250 | 676505 | 15663.2604379 | DE |
52 | 2030 | 14.3260409315 | 14170 | 17980 | 12020 | 650888 | 14906.4880524 | DE |
156 | 2150 | 15.3024911032 | 14050 | 17980 | 7340 | 546906 | 13024.8430733 | DE |
260 | 9516 | 142.36983842 | 6684 | 17980 | 5004 | 501719 | 12371.3372395 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions